Cencora (COR) Stock Forecast & Price Target

Q: What analysts cover Cencora?

Cencora has been rated by research analysts at Citigroup , Evercore , JPMorgan Chase & Co. , Leerink Partners , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$323.59 +2.24 (+0.70%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$323.98 +0.39 (+0.12%)

As of 10/9/2026 07:30 PM Eastern

Compare

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for COR.

Consensus Price Target

$372.07
14.98% Upside

According to the 16 analysts' twelve-month price targets for Cencora, the average price target is $372.07. The highest price target for COR is $440.00, while the lowest price target for COR is $285.00. The average price target represents a forecasted upside of 14.98% from the current price of $323.59.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

Type	Current Forecast 10/10/25 to 10/10/26	1 Month Ago 9/10/25 to 9/10/26	3 Months Ago 7/12/25 to 7/12/26	1 Year Ago 10/10/24 to 10/10/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$372.07	$370.85	$367.75	$320.00
Forecasted Upside	14.98% Upside	15.41% Upside	21.24% Upside	0.63% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Healthcare Companies	Broader Market
Consensus Rating Score	2.81	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	14.98% Upside	927.18% Upside	19.50% Upside
News Sentiment Rating	Positive News See Recent COR News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/7/2026	Leerink Partners 2 of 5 stars	Michael Cherny 4 of 5 stars	Boost Target	Outperform	$380.00 ➝ $388.00	+21.42%
10/6/2026	Weiss Ratings 3 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
9/8/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Reiterated Rating	Sector Perform	$330.00	+0.91%
8/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$331.00 ➝ $395.00	+21.85%
8/7/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$342.00 ➝ $346.00	+7.00%
8/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$382.00 ➝ $390.00	+20.86%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rodgers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$370.00	+18.08%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$412.00 ➝ $430.00	+35.25%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$350.00	+10.18%
8/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
6/24/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Funk Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$280.00 ➝ $285.00	-0.80%
6/10/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$425.00 ➝ $350.00	+25.38%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
1/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Buy
11/10/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$350.00 ➝ $400.00	+10.23%
11/6/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$340.00 ➝ $380.00	+7.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:43 AM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 7, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

Leerink Partners recently raised its price target on Cencora, Inc. from $380.00 to $388.00, maintaining an "outperform" rating, which suggests significant potential upside relative to the current stock price of $316.68.
The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $4.48, which beat analyst consensus estimates of $4.35, alongside revenue of $84.75 billion that exceeded expectations of $84.31 billion.
Cencora, Inc. has a low beta of 0.58, indicating that the stock is less volatile than the broader market, which may appeal to investors seeking stability in their healthcare portfolio.
Institutional investors are increasing their confidence in the company, with Park National Corp OH boosting its stake by 115.2% in the third quarter and MassMutual Private Wealth & Trust FSB increasing its holdings by 62.4%.
The stock currently carries a "Moderate Buy" consensus rating from sixteen brokerages, with an average price target of $370.85, reflecting broad analyst support for the company's outlook.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

The company has a high debt-to-equity ratio of 3.53, which indicates a significant level of leverage relative to its equity, potentially increasing financial risk during economic downturns.
Insider selling activity has been notable, with EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026, which may signal reduced internal confidence.
Cencora, Inc. has a relatively low net margin of 0.79%, meaning the company retains very little profit from each dollar of revenue, which can limit its ability to invest in growth or weather cost increases.
The stock is trading at a price-to-earnings ratio of 23.53, which is higher than the market average, suggesting that the stock may be overvalued relative to its current earnings power.
Short interest has been present in the stock, with 4,311,607 shares shorted as of the most recent record date, indicating that some market participants are betting against the stock's price appreciation.

COR Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $372.07, with a high forecast of $440.00 and a low forecast of $285.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 14.98% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 2 upgrades by analysts.

Cencora has been rated by research analysts at Citigroup, Evercore, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Cencora Recommendations

MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 10/7/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target